title: Insulin aspart: a review.
abstract: Insulin aspart, an analogue of human insulin, which is approved for use in people with diabetes, is more rapidly absorbed and achieves higher plasma concentrations than human soluble insulin following subcutaneous injection. Hence, it has a faster and more effective glucose-lowering action, with superior control of postprandial hyperglycaemia compared with human soluble insulin. Its shorter duration of action makes interprandial and nocturnal hypoglycaemia less of a problem than with human soluble insulin. Insulin aspart is approved for use in continuous subcutaneous infusion and offers a valuable treatment option during pregnancy.
authors.affiliation: Diabetes Research Unit, First Floor, Academic Centre, Llandough Hospital, Penlarn Road, Penarth, South Glamorgan, CF64 2FX, Wales, UK. owens dr@cf.ac.uk
authors.forename: David
authors.initials: D
authors.lastname: Owens
authors.forename: Jiten
authors.initials: J
authors.lastname: Vora
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D061267:Insulin Aspart
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D061267:Insulin Aspart